Bayer files suit against Lupin over plans for generic pill
FRANKFURT (Reuters) - German drugmaker Bayer(BAYGn.DE) has filed a suit in the United States against Indian generic drug maker Lupin(LUPN.NS), to prevent it from selling a version of Bayer's birth-control pill Natazia there.
In the lawsuit, filed on November 28, Bayer said that Lupin is preparing to bring a copy of the Natazia pill, also called Qlaira, to U.S. markets even though Bayer's U.S. patent on the pill runs through 2026.
The complaint said Bayer would be entitled to an award of damages and treble damages for any commercial sale of the alleged copied product.
Lupin was not immediately available for comment.
Natazia is approved in the U.S. as a contraceptive and for the treatment of heavy menstrual bleeding.
Birth-control is one of the most important businesses for Bayer's pharmaceuticals arm, with contraceptive sales of 1.1 billion euros in 2011.
Bayer Pharma AG v Lupin Ltd. and Lupin Pharmaceuticals Inc. (Case 1:12-cv-01592-UNA) was filed with the U.S. District Court, District of Delaware.
(Reporting by Ludwig Burger and Marilyn Gerlach; Editing by Elaine Hardcastle)
- Tweet this
- Share this
- Digg this
- OPEC oil output hits highest since 2012 on Libya, Saudi-Reuters Survey
- With iPhone 6 approved in China, Apple suppliers ready for demand
- Energy, manufacturing to lead Modi, Obama talks
- Modi promises U.S. CEOs a return to market reforms
- Kurds seize Iraq/Syria border post; Sunni tribe joins fight against Islamic State
President Barack Obama and new Prime Minister Narendra Modi discussed trade issues, climate change and the fight against Islamic State militants during an Oval Office meeting on Tuesday, the two leaders told reporters after their meeting. Story | Full Coverage
China final HSBC PMI steady in September on stronger global demand but risks remain Full Article